[go: up one dir, main page]

AR057099A1 - Una forma cristalina, un proceso de preparacion y composicion farmaceutica - Google Patents

Una forma cristalina, un proceso de preparacion y composicion farmaceutica

Info

Publication number
AR057099A1
AR057099A1 ARP060103740A ARP060103740A AR057099A1 AR 057099 A1 AR057099 A1 AR 057099A1 AR P060103740 A ARP060103740 A AR P060103740A AR P060103740 A ARP060103740 A AR P060103740A AR 057099 A1 AR057099 A1 AR 057099A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical preparation
crystal form
composition process
crystalline form
pyridazino
Prior art date
Application number
ARP060103740A
Other languages
English (en)
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057099(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of AR057099A1 publication Critical patent/AR057099A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe una nueva forma cristalina de 7-cloro-N,N,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida, procesos para preparar dicha forma cristalina, y composiciones que comprenden dicha forma mezclada con uno o más excitientes farmacéuticamente aceptables. Estos compuestos son utiles en el tratamiento de enfermedades neurodegenerativas, tumores, dolencias reumáticas y cardíacas. Reivindicacion 1: Una forma cristalina de un compuesto de formula (A) que se denomina forma II.
ARP060103740A 2005-08-29 2006-08-28 Una forma cristalina, un proceso de preparacion y composicion farmaceutica AR057099A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29

Publications (1)

Publication Number Publication Date
AR057099A1 true AR057099A1 (es) 2007-11-14

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103740A AR057099A1 (es) 2005-08-29 2006-08-28 Una forma cristalina, un proceso de preparacion y composicion farmaceutica

Country Status (31)

Country Link
US (1) US7683062B2 (es)
EP (1) EP1924585B1 (es)
JP (1) JP5063600B2 (es)
KR (2) KR20130087059A (es)
CN (1) CN101253176B (es)
AR (1) AR057099A1 (es)
AT (1) ATE531717T1 (es)
AU (1) AU2006285142B2 (es)
BR (1) BRPI0615259A2 (es)
CA (1) CA2619284C (es)
CR (1) CR9723A (es)
CY (1) CY1112317T1 (es)
DK (1) DK1924585T3 (es)
EA (1) EA014164B1 (es)
EC (1) ECSP088209A (es)
ES (1) ES2375841T3 (es)
HR (1) HRP20120073T1 (es)
IL (1) IL189276A (es)
MA (1) MA30000B1 (es)
NO (1) NO20081365L (es)
NZ (1) NZ566087A (es)
PL (1) PL1924585T3 (es)
PT (1) PT1924585E (es)
RS (1) RS52318B (es)
SI (1) SI1924585T1 (es)
TN (1) TNSN08059A1 (es)
TW (1) TW200813060A (es)
UA (1) UA91716C2 (es)
UY (1) UY29771A1 (es)
WO (1) WO2007027525A1 (es)
ZA (1) ZA200801890B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678125C (en) * 2003-11-17 2014-10-14 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
WO2005118586A1 (en) * 2004-06-02 2005-12-15 Sandoz Ag Meropenem intermediate in crystalline form
US8188138B2 (en) * 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
EA201001799A1 (ru) * 2005-10-31 2011-06-30 Янссен Фармацевтика Н.В. Новые способы получения пиперазинильных и диазепанильных производных бензамида
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
WO2010021905A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-n, n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4h-pyridazin0[4,5-b]indole-1-acetamide
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
MX2013002421A (es) * 2010-09-01 2013-05-17 Arena Pharm Inc Sales no hidroscopicas de agonistas de 5-ht2c.
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
NZ630803A (en) * 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
US20050220881A1 (en) 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
CA2619284C (en) 2014-04-29
ZA200801890B (en) 2009-11-25
CR9723A (es) 2008-06-18
DK1924585T3 (da) 2012-02-27
MA30000B1 (fr) 2008-12-01
NZ566087A (en) 2011-03-31
US7683062B2 (en) 2010-03-23
TNSN08059A1 (en) 2009-07-14
HK1123794A1 (en) 2009-06-26
WO2007027525A1 (en) 2007-03-08
JP2009506116A (ja) 2009-02-12
UA91716C2 (ru) 2010-08-25
PL1924585T3 (pl) 2012-08-31
EP1924585A1 (en) 2008-05-28
EA014164B1 (ru) 2010-10-29
AU2006285142B2 (en) 2012-06-14
UY29771A1 (es) 2007-03-30
KR20130087059A (ko) 2013-08-05
CY1112317T1 (el) 2015-12-09
JP5063600B2 (ja) 2012-10-31
ECSP088209A (es) 2008-06-30
RS52318B (sr) 2012-12-31
US20080139569A1 (en) 2008-06-12
CA2619284A1 (en) 2007-03-08
BRPI0615259A2 (pt) 2011-05-17
ES2375841T3 (es) 2012-03-06
ATE531717T1 (de) 2011-11-15
CN101253176A (zh) 2008-08-27
PT1924585E (pt) 2012-01-19
IL189276A (en) 2012-07-31
AU2006285142A1 (en) 2007-03-08
TW200813060A (en) 2008-03-16
HRP20120073T1 (hr) 2012-07-31
NO20081365L (no) 2008-04-03
SI1924585T1 (sl) 2012-09-28
CN101253176B (zh) 2012-04-18
EP1924585B1 (en) 2011-11-02
EA200800716A1 (ru) 2008-08-29
KR20080050577A (ko) 2008-06-09
IL189276A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
AR057099A1 (es) Una forma cristalina, un proceso de preparacion y composicion farmaceutica
BR112022012641A2 (pt) Compostos tricíclicos substituídos
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
GEP20104994B (en) Tetrahydroindolone and tetrahydroindazolone derivatives
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
CR10419A (es) Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
TW200643013A (en) Pyrazoles
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Legal Events

Date Code Title Description
FA Abandonment or withdrawal